Received Nov 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
Patient experienced migraine within 20-30 minutes; This non-serious case was reported by a physician via sales rep and described the occurrence of migraine in a patient who received Men B NVS (Bexsero) for prophylaxis. On an unknown date, the patient received the 1st dose of Bexsero. On an unknown date, 20 min after receiving Bexsero, the patient experienced migraine (Verbatim: Patient experienced migraine within 20-30 minutes). The outcome of the migraine was unknown. It was unknown if the reporter considered the migraine to be related to Bexsero and Bexsero Pre-Filled Syringe Device. It was unknown if the company considered the migraine to be related to Bexsero and Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-NOV-2025 Patient experienced migraine within 20-30 minutes after Bexsero dose 1 immunization. Migraine required visit to emergency room. Physician inquiring if dose 2 should be administered. No further details were provided. The batch number was not provided upon follow- up with the reporter.